美国Atossa Genetics www.atossagenetics.com
我们的第一个产品和服务是乳腺细胞吸取器检测(MASCTSystem™). 这个已经美国国家食品卫生检验局许可的取样及细胞测试系统只需10 分钟的取样，且是无痛的。此项检测可提早几年侦测癌变细胞。

我们透过研究及开发，推出的创新产品和服务来协助医护人员维持女性健康和福利。进而预防、诊断及治疗包括癌症有关乳房的疾病。

我们是一家医疗保健公司专注于开发和销售为乳腺癌风险评估的新型细胞和分子诊断产品。

We are a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer.

Using our patented, FDA-approved Mammary Aspirate Specimen Cytology Test (MASCT) System, a nurse or physician’s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 10 minutes. The NAF sample contains cells (cytology) and molecular diagnostic biomarkers that are useful in finding cancers and pre-cancerous changes, especially Atypical Ductal Hyperplasia (ADH), which confers a higher risk of developing breast cancer.

The FDA has determined, based on clinical trial data, that the MASCT System can be used in the determination and/or differentiation of normal versus premalignant versus malignant cells. Cytology changes in NAF have been shown to occur up to eight years before changes can be picked up by mammography.

Our name comes from Atossa, daughter of Cyrus the Great and wife of Darius I, the King of the Achaemenid Empire. In about 470 BC she became the first woman in recorded history to be diagnosed with breast cancer.